RxDoctor Payments Data

Alexandra Demeglio

Surgical · New York, NYNPI 1417386640

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Optinose US, Inc. at 25.5% of the total. Reporting peaked in 2021 at $878 and has fallen 59.9% since, to $352 in 2025.

$2,488in general payments, 2019–2025

Across 85 payments — averaging $29.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$635
  • Sanofi$585
  • Regeneron Healthcare Solutions, Inc.$490
  • Inspire Medical Systems, Inc.$188
  • AstraZeneca$187
  • Aimmune Therapeutics, Inc.$65
  • plus $339 from 8 others
$28,500in research payments, 2019–2025

Across 4 payments — averaging $7125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$29K

What the payments were for

  • Food & beverage$2,488100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,488 in reported general payments places this provider in the 85th percentile of 1,544 surgical providers in New York.

See all surgical providers in New York

Medicare billing

Part B allowed, 2024
$5,897
Medicare patients
21
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Budesonide41$6,618
Azelastine Hcl55$1,324
Ipratropium Bromide25$692
Fluticasone Propionate51$639
Levocetirizine Dihydrochloride15$445
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$340
Doxycycline Hyclate33$302
Famotidine24$264
Mupirocin26$244
Omeprazole14$222
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$117
Prednisone21$77
Montelukast Sodium12$53

Paid to pharmacies, not to this prescriber.

Other surgical in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →